ETF Foundry
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.
size factor · long-only model fund

Foundry Healthcare Small Size Factor ETF

ETF Foundry Research (hypothetical) · rebalanced monthly

FSIHHYPOTHETICAL MODEL
Since ’99
−38%
Expense Ratio
0.45%
placeholder
Holdings
100
cap-weighted
Inception
Aug 2020
placeholder
Full Sharpe
0.04
Ann. Return (LS)
0.8%
Ann. Volatility
23.0%
Max Drawdown
-84.0%
Test Sharpe ’19–26
-0.22
Test FF5 α (ann.)
-0.4%
vs Fama-French 5
Test FF5 α t-stat
-0.07
not significant
Monthly turnover
19%
of the long leg, per rebalance
Cumulative return (LS)
-38%
over 331 months
This fund holds the long leg only
Long leg Sharpe
0.36
what this fund holds
Long leg ann. return
9.6%
buyable, long-only
Long-short Sharpe
0.04
requires shorting
Bottom bucket ann. return
8.7%
the basket shorted

Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.

Hypothetical growth of $1 — long-short backtest

Gross of the placeholder expense ratio and trading costs · not investor results

331 months

Holdings

Every constituent of the long leg — sort, search or filter by sector

100 of 100 · 100.0% of book
TickerCompanySectorMarket capWeight
1DCTH
DELCATH SYSTEMS INCHealthcare$442M
2.06%
2BNTC
BENITEC BIOPHARMA INCHealthcare$439M
2.04%
3EVMN
EVOMMUNE INCHealthcare$437M
2.04%
4PBYI
PUMA BIOTECHNOLOGY INCHealthcare$434M
2.02%
5CCRN
CROSS COUNTRY HEALTHCARE INCHealthcare$428M
1.99%
6ASMB
ASSEMBLY BIOSCIENCES INCHealthcare$426M
1.98%
7TENX
TENAX THERAPEUTICS INCHealthcare$420M
1.96%
8CBIO
CRESCENT BIOPHARMA INCHealthcare$407M
1.89%
9MOBI
MOBIA MEDICAL INCHealthcare$404M
1.88%
10ENTA
ENANTA PHARMACEUTICALS INCHealthcare$400M
1.86%
11ABEO
ABEONA THERAPEUTICS INCHealthcare$399M
1.86%
12EBS
EMERGENT BIOSOLUTIONS INCHealthcare$394M
1.83%
13TBRG
TRUBRIDGE INCHealthcare$394M
1.83%
14DMAC
DIAMEDICA THERAPEUTICS INCHealthcare$393M
1.83%
15STRO
SUTRO BIOPHARMA INCHealthcare$391M
1.82%
16UPB
UPSTREAM BIO INCHealthcare$382M
1.78%
17EOLS
EVOLUS INCHealthcare$377M
1.76%
18SLP
SIMULATIONS PLUS INCHealthcare$369M
1.72%
19FENC
FENNEC PHARMACEUTICALS INCHealthcare$365M
1.70%
20ZNTL
ZENTALIS PHARMACEUTICALS INCHealthcare$364M
1.69%
21ELMD
ELECTROMED INCHealthcare$349M
1.62%
22CV
CAPSOVISION INCHealthcare$335M
1.56%
23VNDA
VANDA PHARMACEUTICALS INCHealthcare$327M
1.52%
24CARL
CARLSMED INCHealthcare$317M
1.48%
25LYEL
LYELL IMMUNOPHARMA INCHealthcare$311M
1.45%
26FHTX
FOGHORN THERAPEUTICS INCHealthcare$305M
1.42%
27TKNO
ALPHA TEKNOVA INCHealthcare$291M
1.35%
28MASS
908 DEVICES INCHealthcare$278M
1.29%
29SGHT
SIGHT SCIENCES INCHealthcare$274M
1.27%
30TTRX
TURN THERAPEUTICS INCHealthcare$272M
1.26%
31TRDA
ENTRADA THERAPEUTICS INCHealthcare$268M
1.25%
32CNXU
CONEXEU SCIENCES INCHealthcare$263M
1.22%
33ZSQR
Z SQUARED INCHealthcare$260M
1.21%
34QTTB
Q32 BIO INCHealthcare$255M
1.19%
35SRZN
SURROZEN INCHealthcare$255M
1.19%
36RNAC
CARTESIAN THERAPEUTICS INCHealthcare$243M
1.13%
37ARTV
ARTIVA BIOTHERAPEUTICS INCHealthcare$241M
1.12%
38GLSI
GREENWICH LIFESCIENCES INCHealthcare$240M
1.11%
39RXST
RXSIGHT INCHealthcare$230M
1.07%
40SMTI
SANARA MEDTECH INCHealthcare$229M
1.07%
41SPOK
SPOK HOLDINGS INCHealthcare$222M
1.03%
42UTMD
UTAH MEDICAL PRODUCTS INCHealthcare$222M
1.03%
43KPTI
KARYOPHARM THERAPEUTICS INCHealthcare$216M
1.00%
44SENS
SENSEONICS HOLDINGS INCHealthcare$214M
0.99%
45KROS
KEROS THERAPEUTICS INCHealthcare$211M
0.98%
46AGEN
AGENUS INCHealthcare$209M
0.97%
47RNA
ATRIUM THERAPEUTICS INCHealthcare$208M
0.97%
48IMUX
IMMUNIC INCHealthcare$207M
0.96%
49BDSX
BIODESIX INCHealthcare$204M
0.95%
50FOCL
FOCAL INCHealthcare$204M
0.95%
51DTIL
PRECISION BIOSCIENCES INCHealthcare$203M
0.95%
52ANIK
ANIKA THERAPEUTICS INCHealthcare$203M
0.94%
53AMWL
AMERICAN WELL CORPHealthcare$199M
0.93%
54TNXP
TONIX PHARMACEUTICALS HOLDING CORPHealthcare$198M
0.92%
55DERM
JOURNEY MEDICAL CORPHealthcare$197M
0.92%
56ACOG
ALPHA COGNITION INCHealthcare$185M
0.86%
57PDEX
PRO DEX INCHealthcare$183M
0.85%
58INFU
INFUSYSTEM HOLDINGS INCHealthcare$180M
0.84%
59INGN
INOGEN INCHealthcare$178M
0.83%
60KRRO
KORRO BIO INCHealthcare$177M
0.82%
61ARCT
ARCTURUS THERAPEUTICS HOLDINGS INCHealthcare$172M
0.80%
62CRBP
CORBUS PHARMACEUTICALS HOLDINGS INCHealthcare$167M
0.78%
63LENZ
LENZ THERAPEUTICS INCHealthcare$162M
0.76%
64OWLT
OWLET INCHealthcare$162M
0.76%
65RCEL
AVITA MEDICAL INCHealthcare$157M
0.73%
66UNCY
UNICYCIVE THERAPEUTICS INCHealthcare$144M
0.67%
67PMN
PROMIS NEUROSCIENCES INCHealthcare$136M
0.63%
68VTVT
VTV THERAPEUTICS INCHealthcare$130M
0.60%
69AARD
AARDVARK THERAPEUTICS INCHealthcare$128M
0.59%
70JYNT
JOINT CORPHealthcare$127M
0.59%
71CUE
CUE BIOPHARMA INCHealthcare$126M
0.59%
72OPRX
OPTIMIZERX CORPHealthcare$126M
0.58%
73SPRB
SPRUCE BIOSCIENCES INCHealthcare$120M
0.56%
74CPIX
CUMBERLAND PHARMACEUTICALS INCHealthcare$103M
0.48%
75ICCC
IMMUCELL CORPHealthcare$101M
0.47%
76VRCA
VERRICA PHARMACEUTICALS INCHealthcare$96M
0.45%
77PTHS
PELTHOS THERAPEUTICS INCHealthcare$94M
0.44%
78LIXT
LIXTE BIOTECHNOLOGY HOLDINGS INCHealthcare$91M
0.42%
79PARK
PARK DENTAL PARTNERS INCHealthcare$88M
0.41%
80RLYB
RALLYBIO CORPHealthcare$87M
0.41%
81CSBR
CHAMPIONS ONCOLOGY INCHealthcare$85M
0.40%
82NRXS
NEURAXIS INCHealthcare$84M
0.39%
83FRMM
FORUM MARKETS INCHealthcare$83M
0.38%
84PIII
P3 HEALTH PARTNERS INCHealthcare$78M
0.36%
85ACET
ADICET BIO INCHealthcare$76M
0.35%
86ATRA
ATARA BIOTHERAPEUTICS INCHealthcare$76M
0.35%
87CLNN
CLENE INCHealthcare$76M
0.35%
88NMAD
NOMAD POWER SOLUTIONS INCHealthcare$72M
0.33%
89SCLX
SCILEX HOLDING COHealthcare$72M
0.33%
90AGPU
AXE COMPUTE INCHealthcare$72M
0.33%
91LNSR
LENSAR INCHealthcare$70M
0.33%
92LONA
LEONABIO INCHealthcare$68M
0.32%
93IMA
IMAGENEBIO INCHealthcare$61M
0.28%
94EDSA
EDESA BIOTECH INCHealthcare$59M
0.27%
95SNWV
SANUWAVE HEALTH INCHealthcare$55M
0.26%
96INKT
MINK THERAPEUTICS INCHealthcare$53M
0.25%
97XLO
XILIO THERAPEUTICS INCHealthcare$53M
0.25%
98MCRB
SERES THERAPEUTICS INCHealthcare$52M
0.24%
99EXOZ
EXOZYMES INCHealthcare$51M
0.24%
100TIL
INSTIL BIO INCHealthcare$50M
0.23%

Full long-leg book as of July 2026 · cap-weighted · total market cap $21.48B. Hypothetical model holdings — not a registered fund’s portfolio.

Sector Breakdown

1 sectors
Healthcare
100.0%

Portfolio Style

Size × value map of the long-leg book

100 classified
Value
Blend
Growth
Large
Mid
Small
·
·
·
·
·
·
48%47
16%18
19%17

Share of long-leg capital by market cap × book-to-market, using terciles of the 499-name universe at July 2026. Rows: Large ≥ $3.6B, Small < $964M. Columns: Value ≥ 0.67, Growth < 0.37 B/M. The dot marks the capital-weighted centroid of the book — 0% toward Large, 32% toward Growth. +17% unclassified (18 missing size/value). Hypothetical holdings — descriptive, not realized P&L.

Tilt over time
Size tilt0% → Large
SmallLarge
Value ↔ growth tilt32% → Growth
ValueGrowth

Capital-weighted centroid of the long leg, December 1998July 2026; the right-hand end is the same value as the box’s dot. 100 names now. Hypothetical holdings — descriptive, not P&L.

Constraint checks

How this book measures against the concentration and liquidity rules — as implemented here

How this book was built

These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.

Passed
5
Failed
1
Not tested
1
Independent checks
7

7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.

1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.

  • Days required to liquidate the largest position at 20% of one day's dollar volume.

    Required
    <= 7.0 days
    Actual
    27.6 days
    Margin
    -20.6 days
  • No more than 15% of net assets may be held in illiquid investments.

    Required
    <= 15.0%
    Actual
    14.6%
    Margin
    0.4%

    Close to the line. The engine flags this verdict as one a routine data rebuild could flip. Read it as borderline rather than settled — the margin beside it is the whole story.

Reported separately — arithmetically implied

Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.

1 verdict(s) sit within 1.0pp of their limit and can be flipped by a routine data rebuild; do not headline them, and always show the margin.

Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700

Measured on the 2026-07 formation date across 100 holdings (cap-weighted). A different formation date can produce different verdicts.

Derivatives risk (Rule 18f-4)

Whether this long-only book is subject to the VaR tests at all

This assessment describes the long-only book this fund holds — the top bucket only.

Governing rule
Rule 18f-4(c)(4) limited derivatives user exception

This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.

Limited derivatives user exceptionby construction

Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.

Qualifies
Required
<= 10% of net assets
Exposure
0% of net assets
Margin
+10pp

No confidence interval: this follows from portfolio construction, not from an estimate.

Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.

Informational — does not govern

This fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.

Measured
1.8 (95% CI 1.3-2.1)
x reference VaR
Limit
2.00x
<= 2.00x reference VaR
Fund VaR
17.0%
99% / 20d
Reference
9.6%
FF5 market (mkt)

historical method · 331 monthly observations · about 3.3 in the 99% tail · paired percentile bootstrap over months

Same test, three estimators
historical
1.77x
within
parametric
1.71x
within
cornish fisher
1.62x
within

The estimators agree, which is mild evidence the number isn’t an artefact of one method.

Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.

The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.

See the long-short verdict on the factor page →

Since publication

Did the edge survive the paper coming out?

published 1981
Entirely since publication
All 331 months of our record post-date the 1981 paper.
Sharpe 0.040.8% p.a.January 1999July 2026

There is no “before” to compare against — the predictor was already public when our data begins, so every month shown is out-of-sample relative to the original study.

Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.

Consistency across eras

Is this record broadly durable, or one regime?

26 windows
Positive windows
38%
10 of 26 3-year windows made money
Worst window
-0.80
Sharpe, January 2021 – December 2023
January 1999July 2026
Median Sharpe
-0.11
Dispersion
0.55
Best window
1.15

3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.

Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.

Returns

Long leg is what this fund holds — long-short is shown for reference

since January 1999
Trailing
PeriodLong legLong-short
1 yearcum.38.3%9.4%
3 yearsp.a.3.4%-5.2%
5 yearsp.a.-5.9%-10.8%
10 yearsp.a.3.1%-5.7%
Since inceptionp.a.6.3%-1.7%
Calendar years
YearLong legLong-short
20267 mo6.1%1.2%
202518.8%0.7%
2024-0.4%-4.0%
2023-6.9%-8.4%
2022-23.5%-19.1%
2021-20.4%-35.1%
202031.9%14.1%
201924.1%2.8%
2018-20.0%-24.0%
201731.5%9.5%
2016-15.8%-9.6%
2015-5.5%-11.2%
20146.3%-15.6%
201381.0%27.4%
201223.8%5.7%
2011-14.7%-23.3%
2010-2.6%-6.6%
200917.3%-3.3%
2008-37.1%-17.0%
20071.4%-5.6%
200620.3%13.2%
20057.4%-2.2%
200417.0%13.9%
200378.7%50.0%
2002-25.7%-4.9%
200127.5%44.1%
200014.4%-16.6%
199926.6%26.4%

Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.

Fund Facts

Ticker (pseudo)FSIH
IssuerETF Foundry Research (hypothetical)
SeriesHypothetical Model Portfolio Series (not a registered trust)
Expense ratio0.45% (placeholder)
Inception2020-08-23 (placeholder)
Listing exchangeNot listed (hypothetical)
CUSIPNot applicable (hypothetical model portfolio)
RebalanceMonthly
Holdings as ofJuly 2026
Total mkt cap (long leg)$21.48B

Methodology

The Foundry Healthcare Small Size Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a Small Size signal and holds the top quintile with the lowest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.

This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.

Documents (draft — hypothetical)

Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.

Summary Prospectus

Objective, fees, strategy, and key risks.

View →
Prospectus

Full strategy, model methodology, and risks.

View →
Statement of Additional Information

Policies, construction, and governance.

View →
Fact Sheet

One-page snapshot with top holdings.

View →
Daily Holdings

Full current constituent list.

View →

DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.